What is glutamic acid decarboxylase (GAD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Glutamic Acid Decarboxylase (GAD)?

Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the conversion of glutamic acid (glutamate) into gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. 1

Biochemical Function

GAD exists in two main isoforms—GAD65 and GAD67—which are encoded by separate genes and have distinct regulatory mechanisms 2, 3. Both isoforms are pyridoxal phosphate (PLP)-dependent enzymes that perform the same catalytic function: the alpha-decarboxylation of glutamate to produce GABA and CO2 4.

Tissue Distribution and Expression

GAD is widely expressed in two primary locations:

  • Central nervous system: Found in inhibitory neurons throughout the brain, localized to axon terminals, soma, and dendrites 5, 2
  • Pancreatic β-cells: Where GABA produced by GAD plays a role in regulating insulin secretion 1

Clinical Significance in Diabetes

In the context of diabetes, GAD is most clinically relevant as an autoimmune marker. Autoantibodies to GAD (particularly GAD65) are one of the key islet autoantibodies used for:

  • Screening for presymptomatic type 1 diabetes alongside antibodies to insulin, islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8) 6, 7
  • Classifying diabetes type in adults with overlapping phenotypic features (younger age at diagnosis, unintentional weight loss, ketoacidosis, rapid progression to insulin) 6
  • Identifying latent autoimmune diabetes of adults (LADA), where approximately 5-10% of White adults presenting with type 2 diabetes phenotype have GAD antibodies that predict insulin dependency 8

Diagnostic Application

The presence of multiple islet autoantibodies including anti-GAD defines Stage 1 type 1 diabetes (with normoglycemia) and carries a 44% 5-year risk of developing symptomatic diabetes 6, 7. When GAD antibodies are detected alongside other islet autoantibodies and dysglycemia (Stage 2), the risk increases to 60% by 2 years 6, 7.

Clinical Significance in Neurological Disorders

GAD antibodies are also associated with GAD antibody-spectrum disorders (GAD-SD), which include 1, 9:

  • Stiff-person syndrome (SPS)
  • Cerebellar ataxia
  • Limbic encephalitis
  • Drug-resistant epilepsy
  • Cognitive impairment

These neurological manifestations may occur independently or alongside type 1 diabetes, as GAD is expressed in both pancreatic β-cells and the central nervous system 1, 10.

Important Testing Considerations

GAD autoantibody testing should only be performed in accredited laboratories with established quality control programs 8. The clinical utility differs by context:

  • Screening: Recommended for first-degree relatives of type 1 diabetes patients or in research settings 8, 11
  • Diagnosis: Useful for classifying diabetes type in ambiguous presentations 6
  • Monitoring: No role for repeated GAD antibody measurement in established type 1 diabetes outside research protocols 8

References

Research

Glutamic acid decarboxylase (GAD) immunocytochemistry of developing rabbit hippocampus.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 1986

Research

Glutamic acid decarboxylase autoantibodies and neurological disorders.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002

Research

Glutamic acid decarboxylase--gene to antigen to disease.

Journal of internal medicine, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.